Optimizing therapy early in multiple sclerosis: An evidence-based view (Q26783070)

6

object named as

Bernd C Kieseier

0 references

Heinz Wiendl

5

object named as

Heinz Wiendl

0 references

Nicola De Stefano

2

object named as

Nicola De Stefano

0 references

author name string

Maria Pia Sormani

3

0 references

Bart Van Wijmeersch

Multiple Sclerosis and Related Disorders

4

0 references

language of work or name

English

0 references

publication date

September 2015

0 references

published in

1 reference

Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis

PubMed

volume

4

0 references

issue

5

0 references

page(s)

460-9

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon β: Implications for clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Anti-JC virus antibodies: implications for PML risk stratification

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

JC virus antibody status underestimates infection rates

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Immunopathogenesis of the multiple sclerosis lesion

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Switching therapies in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Clinical relevance of brain volume measures in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Dimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Teriflunomide and its mechanism of action in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Fingolimod: a review of its use in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Pathology of multiple sclerosis and related inflammatory demyelinating diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

The molecular basis of neurodegeneration in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Management of relapsing-remitting multiple sclerosis in Latin America: practical recommendations for treatment optimization

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Mu

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

First-dose effects of fingolimod: Pooled safety data from three phase 3 studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

The relationship between whole brain volume and disability in multiple sclerosis: a comparison of normalized gray vs. white matter with misclassification correction.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

The measurement and clinical relevance of brain atrophy in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Association between pathological and MRI findings in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Treatment optimization in MS: Canadian MS Working Group updated recommendations.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Predicting responders to therapies for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Determinants of interferon β efficacy in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Defining and scoring response to IFN-β in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Sorting out the risks in progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Alemtuzumab treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

PML in a patient without severe lymphocytopenia receiving dimethyl fumarate

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

PML in a patient with lymphocytopenia treated with dimethyl fumarate

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Inflammatory cortical demyelination in early multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

The role of magnetic resonance techniques in understanding and managing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Cortical demyelination and diffuse white matter injury in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Evidence for a two-stage disability progression in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Clinical outcome measures for research in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Multiple sclerosis: current treatment algorithms.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

MRI activity and neutralising antibody as predictors of response to interferon treatment in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Brain atrophy and lesion load predict long term disability in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Thalamic atrophy is associated with development of clinically definite multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Patterns of contrast enhancement in the brain and meninges

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Measures in the first year of therapy predict the response to interferon β in MS

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Scoring treatment response in patients with relapsing multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Magnetic resonance imaging outcomes from a phase III trial of teriflunomide

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Refining response to treatment as defined by the Modified Rio Score.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

JC-virus seroconversion in multiple sclerosis patients receiving natalizumab.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS).

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Evolving expectations around early management of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Best practice in the use of natalizumab in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Gray matter damage predicts the accumulation of disability 13 years later in MS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Multiple sclerosis therapeutic strategies: Use second-line agents as first-line agents when time is of the essence.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Assessing treatment response to interferon-β: is there a role for MRI?

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Fingolimod after natalizumab and the risk of short-term relapse

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Defining the clinical course of multiple sclerosis: the 2013 revisions

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

MRI predictors of cognitive outcome in early multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Association of MRI metrics and cognitive impairment in radiologically isolated syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Switching multiple sclerosis patients with breakthrough disease to second-line therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Dimethyl fumarate for treating relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

The safety and efficacy of IFN-beta products for the treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Fingolimod for the treatment of relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021

Disease-modifying agents in the treatment of multiple sclerosis: a review of long-term outcomes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.007

7 January 2021